BACKGROUND EZETIMIBE USE AMONG PARTICIPANTS IN THE CLEAR OUTCOMES TRIAL
Therapeutic Area: ASCVD/CVD Risk Reduction Background: The Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial randomized statin-intolerant patients with, or at high risk for, atherosclerotic cardiovascular disease (ASCVD) to bempedoic acid or placebo and assess...
Saved in:
Main Authors: | Luke J. Laffin (Author), Danielle Brennan (Author), LeAnne Bloedon (Author), Na Li (Author), Steven E. Nissen (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of pulse pressure with death, myocardial infarction, and stroke among cardiovascular outcome trial participants
by: Neel Agarwal, et al.
Published: (2024) -
Ezetimibe and Cancer: Is There a Connection?
by: Jia Gu, et al.
Published: (2022) -
Meta-analysis and trial sequential analysis of ezetimibe for coronary atherosclerotic plaque compositions
by: Bofeng Chai, et al.
Published: (2023) -
MONOTHERAPY EZETIMIBE-INDUCED RHABDOMYOLYSIS
by: Niharika Baviriseaty, MD
Published: (2024) -
Formulation and Evaluation of Ezetimibe Nanoparticles
by: bijps, et al.
Published: (2017)